Method of viral inhibition
AssigneeMonash University
InventorsJohanna Elisabeth FRASER, David Andrew JANS, Kylie Michelle WAGSTAFF
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.
Claims13
1-14. (canceled)
A method of preventing or delaying the onset of one or more symptoms of dengue virus (DENV) in a subject at risk of being exposed to DENV, comprising:
- administering a daily dose of N-(4-hydroxyphenyl) retinamide (4-HPR) to the subject of up to 4,000 mg/m2/day during a period of time in which the subject is at risk of exposure, wherein the subject is not being administered an anti-viral agent other than 4-HPR.
A method of preventing or delaying the onset of one or more symptoms of dengue virus (DENV) in a subject at risk of being exposed to DENV, comprising:
- administering a daily dose of 4-HPR of up to 4,000 mg/m2/day for 1 to 5 days prior to being exposed to DENV;
- administering a daily dose of N-(4-hydroxyphenyl) retinamide (4-HPR) to the subject of up to 4,000 mg/m2/day during the period of time in which the subject is at risk of exposure;
- and
- administering a daily dose of 4-HPR of up to 4,000 mg/m2/day for 1 to 14 days after being exposed to DENV, wherein the subject is not being administered an anti-viral agent other than 4-HPR.
Dependencies are inferred from the claim text.